Spravato Therapy
Breakthrough FDA-Approved Treatment for Treatment-Resistant Depression
Spravato® (Esketamine) nasal spray delivers rapid symptom relief within hours or days for adults with treatment-resistant depression who have not found success with traditional antidepressants.
Condition We Treat
Treatment-Resistant Depression (TRD): Specifically FDA-approved for adults with Major Depressive Disorder who have not achieved adequate relief after trying two or more oral antidepressant treatments.
The Spravato Patient Journey
1
Free Consultation
Ensure you meet the FDA criteria (having tried and failed at least two different antidepressants).
2
Psychiatric Evaluation
Meet with our doctor to review your full medical history, ensure there are no contraindications, and develop a treatment plan.
3
REMS Registration & Insurance
Spravato has a specific FDA safety protocol (REMS). We register you in the system and obtain insurance authorization.
4
In-Clinic Administration
You administer the nasal spray yourself under our direct supervision. You then relax in our observation room for 2 hours while we monitor your blood pressure and side effects.
5
Transportation & Maintenance
You must have a trusted friend or family member drive you home. Sessions start twice a week and gradually taper to once a week or less.
Clinical Efficacy & Data
Spravato Clinical Efficacy
Symptom Relief Metrics
Rapid Action:
Patients often experience relief within hours to days, rather than weeks.
Statistically significant improvement in depressive symptoms at 4 weeks compared to placebo.
Sustained Response:
Up to 70% of patients who remain on treatment show a sustained positive response over time.
Demonstrated efficacy in reducing depressive symptoms and suicidal ideation rapidly.
FAQ – Spravato Therapy
Spravato is FDA-approved for adults with treatment-resistant depression (TRD) who have not responded adequately to at least two different oral antidepressants.
You self-administer the nasal spray under provider supervision in our clinic, then relax in a quiet, comfortable treatment room during a required two-hour observation period to ensure your safety and comfort.
No. Because Spravato can cause temporary side effects such as sedation, dizziness, or dissociation, you must have a trusted friend, family member, or ride service transport you home after your two-hour monitoring period.
Unlike traditional oral antidepressants that often require 4 to 8 weeks to take effect, Spravato is rapid-acting and can deliver noticeable symptom reduction within hours or days.
Yes, Spravato is covered by most major insurance plans for treatment-resistant depression. Our patient care team handles all prior authorizations and verifies your benefits before treatment begins.
